Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly

Table 2

Linear regression for predicting change in GH (delta GH) [first two panels], and IGF-1 (delta IGF-1) [last 2 panels], before and after treatment with SS-a based on histological markers, corrected for baseline GH and IGF-1 values respectively.

Variable	Change in GH		Change in IGF-1
	Beta (95% CI)	p-value	Beta (95% CI)	p-value
Ki-67	0.17 (−0.97, 1.31)	0.757	17.15 (−75.75, 110.05)	0.704
SSTR-2	−0.82 (−1.93, 0.28)	0.136	−38.51 (−132.52, 55.50)	0.404
SSTR-5	−0.17 (−1.11, 1.46)	0.783	23.06 (−82.28, 128.40)	0.653
ZAC-1	−1.53 (−2.80, −0.26)	0.021	91.15 (−20.17, 202.49)	0.103
E-cadherin	0.27 (−0.98, 1.53)	0.652	7.75 (−95.16, 110.66)	0.877
AIP	0.02 (−2.34, 2.39)	0.985	132.65 (−106.12, 371.41)	0.260
Granulation	1.85 (−0.99, 4.69)	0.189	109.90 (−95.03, 314.83)	0.277